DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Squamous Cell Carcinoma Treatment Landscape. Click here to read more @ Squamous Cell Carcinoma Pipeline Outlook
Key Takeaways from the Squamous Cell Carcinoma Pipeline Report
- In January 2025:- Incyte Corporation:- This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma. A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma
- In January 2025:- Replimune Inc.:- RP1 is a selectively replication competent herpes simplex virus type 1(HSV-1). This is a Phase 1/2, open-label, multicenter repeat-dosing study of RP1 alone and in combination with nivolumab in patients with advanced malignancies, and contains both single agent dose escalation, dose expansion to include nivolumab, and the combination in multiple Phase 2 cohorts in individual tumor types.
- In January 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
- DelveInsight’s Squamous Cell Carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Squamous Cell Carcinoma treatment.
- The leading Squamous Cell Carcinoma Companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
- Promising Squamous Cell Carcinoma Therapies such as SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.
Discover groundbreaking developments in Squamous Cell Carcinoma therapies! Gain in-depth knowledge of key Squamous Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Squamous Cell Carcinoma Clinical Trials Assessment
Squamous Cell Carcinoma Emerging Drugs Profile
- NBTXR-3: Nanobiotix
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.
- mRNA-4157: Moderna Therapeutics
mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.
- HB-200: Hookipa Pharma
HB-200 is HOOKIPA’s lead oncology candidate engineered with the company’s proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.
- MCLA-158: Merus
MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.
- HFB-301001: HiFiBiO
HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.
Stay informed about the Squamous Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Squamous Cell Carcinoma Unmet Needs
Squamous Cell Carcinoma Companies and Therapies
- Sichuan Baili Pharmaceutical Co., Ltd.: SI-B001
- InflaRx GmbH: IFX-1
- Merck Sharp & Dohme LLC: MK-3475A
- ImmunityBio Inc.- Aldoxorubicin HCl
- Incyte Corporation: INCB099280
Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Transform your understanding of the Squamous Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Squamous Cell Carcinoma Pipeline Report
- Coverage- Global
- Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
- Squamous Cell Carcinoma Therapies- SI-B001, IFX-1, Afatinib 40 MG, Pembrolizumab Injection, MK-3475A, and others.
- Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Content
- Introduction
- Executive Summary
- Squamous Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Squamous Cell Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- NBTXR-3: Nanobiotix
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HB-200: Hookipa Pharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HFB-301001: HiFiBiO
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Squamous Cell Carcinoma Key Companies
- Squamous Cell Carcinoma Key Products
- Squamous Cell Carcinoma- Unmet Needs
- Squamous Cell Carcinoma- Market Drivers and Barriers
- Squamous Cell Carcinoma- Future Perspectives and Conclusion
- Squamous Cell Carcinoma Analyst Views
- Squamous Cell Carcinoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight